EGLT - Egalet Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
0.105
+0.002 (+1.94%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.103
Open0.101
Bid0.000 x 3000
Ask0.000 x 1000
Day's Range0.082 - 0.105
52 Week Range0.075 - 1.570
Volume470,062
Avg. Volume1,102,836
Market Cap5.738M
Beta (3Y Monthly)1.15
PE Ratio (TTM)N/A
EPS (TTM)-0.903
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • The Wall Street Journal22 days ago

    [$$] Drug Maker Egalet Buys More Times With Bondholder Pact

    Egalet Corp., which earlier this year issued a “going concern” warning, has reached a forbearance agreement with a group of bondholders and said it is in talks with other creditors about a possible debt ...

  • The Wall Street Journal22 days ago

    [$$] Egalet Enters Forbearance Pact With Some Bondholders

    Corp., which earlier this year issued a “going concern” warning, has reached a forbearance agreement with a group of bondholders and said it is in talks with other creditors about a possible debt restructuring. Egalet said a Nasdaq delisting is among the “triggering events” that could accelerate its financial obligations with debtholders. The forbearance agreement, which expires Oct. 14, buys it time to negotiate with the 13% bondholders, and the company said it is also in talks with “certain holders” of its 6.5% and 5.5% convertible senior notes about “potential strategic alternatives,” including debt restructuring.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Argos Therapeutics, Triumph Group, Rigel Pharmaceuticals, Egalet, Hertz Global, and ACADIA Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Argos ...

  • Zacks Small Cap Research2 months ago

    EGLT: Egalet 2Q:18 Results

    Egalet Corporation (EGLT) released second quarter 2018 results on August 8 and filed form 10-Q on August 9 posting revenues of $7.4 million and a net loss of ($0.22) per share. The company continues to develop partnerships and add products to preferred formulary positions adding several new PBMs and plans to its portfolio. Second quarter revenues of $7.4 million were comprised of Sprix sales of $5.4 million, Oxaydo sales of $1.7 million and Arymo sales of $0.4 million.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of EGLT earnings conference call or presentation 8-Aug-18 12:30pm GMT

    Q2 2018 Egalet Corp Earnings Call

  • ACCESSWIRE2 months ago

    Egalet Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Egalet Corporation (NASDAQ: EGLT ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern Time. ...

  • Associated Press2 months ago

    Egalet: 2Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 17 cents per share. The pain medicine maker posted revenue of $7.4 million ...

  • Egalet Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    Egalet Reports Second Quarter 2018 Financial Results

    --Improvements in formulary status for key products-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , Aug. 8, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), ...

  • Benzinga2 months ago

    Preview: Egalet's Q2 Earnings

    On Wednesday,  Egalet (NASDAQ: EGLT ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Egalet EPS will likely ...

  • GlobeNewswire3 months ago

    Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Egalet ...

  • Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018
    PR Newswire3 months ago

    Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018

    WAYNE, Penn., July 25, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • Egalet Appoints Industry Veteran John Varian to Board of Directors
    PR Newswire4 months ago

    Egalet Appoints Industry Veteran John Varian to Board of Directors

    WAYNE, Pa., June 7, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the appointment of John Varian to its board of directors. Over the past three decades, Mr. Varian has helped companies establish strategic direction, raise capital, launch pharmaceutical products, structure and negotiate corporate alliances, communicate with investors and execute business development transactions.

  • Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference
    PR Newswire4 months ago

    Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference

    WAYNE, Pa., June 4, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced Bob Radie, president and chief executive officer, will present in panels at two upcoming conferences in June. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO® ER (morphine sulfate) extended-release tablets for oral use —CII, developed using Egalet's proprietary Guardian™ Technology, OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII and SPRIX® (ketorolac tromethamine) Nasal Spray.

  • Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray
    PR Newswire5 months ago

    Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray

    WAYNE, Pa. , May 29, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing ...

  • Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)
    Simply Wall St.5 months ago

    Breakeven On The Horizon For Egalet Corporation (NASDAQ:EGLT)

    Egalet Corporation’s (NASDAQ:EGLT): Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. The US$29.69M market-cap company’s loss lessens since it announcedRead More...

  • Zacks Small Cap Research5 months ago

    EGLT: Partnerships and Formulary Adds Impressive; Waiting for Revenue Catch Up

    Revenues increased 15% on prescription growth of 115%. The results were distinguished by a marked decline in expenses, particularly R&D costs as the company streamlines its structure to emphasize profitability. The company continues to develop partnerships and add products to preferred formulary positions.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of EGLT earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Egalet Corp Earnings Call

  • Associated Press5 months ago

    Egalet: 1Q Earnings Snapshot

    The Wayne, Pennsylvania-based company said it had a loss of 26 cents per share. The pain medicine maker posted revenue of $6.3 million in the period. The company's shares closed at 73 cents. A year ago, ...

  • Egalet Reports First Quarter 2018 Financial Results
    PR Newswire5 months ago

    Egalet Reports First Quarter 2018 Financial Results

    --Multiple advances in formulary status for key products-- --Realigned and re-focused sales force-- --Company to host conference call today at 8:30 AM EDT-- WAYNE, Pa. , May 8, 2018 /PRNewswire/ -- Egalet ...

  • PR Newswire5 months ago

    Egalet Announces National Pharmacy Benefit Manager to Cover SPRIX® Nasal Spray and ARYMO® ER

    --SPRIX Nasal Spray placed in preferred position-- --Plan covers 3.5 million member lives-- WAYNE, Pa. , May 7, 2018 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated ...

  • ACCESSWIRE6 months ago

    Egalet to Present at the 3rd Annual Disruptive Growth & Healthcare Conference

    WAYNE, PA / ACCESSWIRE / May 2, 2018 / Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that Bob Radie, Egalet's president and chief executive officer, will present at the 3rd Annual Disruptive Growth & Healthcare Conference in New York City. The investor presentation will be audio webcast live and available for replay at Egalet's website at http://egalet.investorroom.com/eventsandwebcasts. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.

  • Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse
    PR Newswire6 months ago

    Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse

    WAYNE, Pa., April 30, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced data on ARYMO ER (morphine sulfate) extended-release (ER) tablets CII were presented in four poster presentations at the 34th Annual Meeting of the American Academy of Pain Medicine (AAPM) in Vancouver, Canada. The data support the need for a multifaceted approach including abuse-deterrent opioids such as ARYMO ER to address the prescription opioid misuse and abuse crisis. Arymo ER has physical and chemical properties expected to make abuse by injection difficult.

  • Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018
    PR Newswire6 months ago

    Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018

    WAYNE, Pa., April 24, 2018 /PRNewswire/ -- Egalet Corporation (EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced that its first quarter 2018 financial results will be released on Tuesday, May 8, 2018. Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions.